The bill proposes significant changes to the "Uniform Controlled Substances Act" by revising Section 21-28-1.02, which defines various terms related to controlled substances. The new version of this section, effective January 1, 2023, will include updated definitions, such as "acute pain," "chronic intractable pain," and "opioid therapy," among others.

In addition to the revisions to definitions, the bill introduces new regulations for practitioners prescribing opioids, particularly for acute pain treatment. It mandates that initial prescriptions for adults and minors cannot exceed a seven-day supply and must be the lowest effective dosage. Practitioners are required to discuss the risks of opioid use and alternatives with patients or their guardians, document these discussions, and offer naloxone with prescriptions.

The bill emphasizes the importance of reviewing the prescription drug monitoring program prior to initiating opioid therapy and maintaining thorough records. It allows the director of health to develop regulations regarding opioid use in pain management. Furthermore, the bill repeals Chapter 37.5 of Title 5, which relates to intractable pain treatment. Overall, the bill seeks to ensure responsible prescribing practices while addressing the needs of patients with chronic pain conditions.

Statutes affected:
3259: 21-28-1.02